Latest & greatest articles for cardiovascular disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cardiovascular disease

21. Management of Dyslipidemia for Cardiovascular Disease Risk Reduction: Synopsis of the 2020 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. (Abstract)

Management of Dyslipidemia for Cardiovascular Disease Risk Reduction: Synopsis of the 2020 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. In June 2020, the U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) released a joint update of their clinical practice guideline for managing dyslipidemia to reduce cardiovascular disease risk in adults. This synopsis describes the major recommendations.On 6 August to 9

2020 Annals of Internal Medicine

22. Interventions to Improve Statin Tolerance and Adherence in Patients at Risk for Cardiovascular Disease : A Systematic Review for the 2020 U.S. Department of Veterans Affairs and U.S. Department of Defense Guidelines for Management of Dyslipidemia. (Abstract)

Interventions to Improve Statin Tolerance and Adherence in Patients at Risk for Cardiovascular Disease : A Systematic Review for the 2020 U.S. Department of Veterans Affairs and U.S. Department of Defense Guidelines for Management of Dyslipidemia. Strategies to improve patients' tolerance of and adherence to statins may enhance the effectiveness of dyslipidemia treatment in those at risk for cardiovascular disease (CVD).To assess the benefits and harms of interventions to improve statin

2020 Annals of Internal Medicine

23. Cardiovascular Risk Profile in Dupuytren’s Disease: A Systematic Review and Meta-Analysis. Full Text available with Trip Pro

Cardiovascular Risk Profile in Dupuytren’s Disease: A Systematic Review and Meta-Analysis. Cardiovascular Risk Profile in Dupuytren’s Disease: A Systematic Review and Meta-Analysis. | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement (...) of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article Cardiovascular Risk Profile in Dupuytren’s Disease: A Systematic Review and Meta-Analysis. Sylvain Mathieu, Bruno Pereira, Frederic Dutheil, Martin Soubrier Sylvain Mathieu CHU Gabriel Montpied: Centre Hospitalier Universitaire Gabriel Montpied Corresponding Author ORCiD: https://orcid.org/0000-0003-2017-3227 Bruno Pereira CHU Gabriel Montpied: Centre Hospitalier

2020 Research Square

24. Machine Learning for Integrating Social Determinants in Cardiovascular Disease Prediction Models: A Systematic Review Full Text available with Trip Pro

Machine Learning for Integrating Social Determinants in Cardiovascular Disease Prediction Models: A Systematic Review Machine Learning for Integrating Social Determinants in Cardiovascular Disease Prediction Models: A Systematic Review | medRxiv Search for this keyword Machine Learning for Integrating Social Determinants in Cardiovascular Disease Prediction Models: A Systematic Review Yuan Zhao , Erica P Wood , Nicholas Mirin , Rajesh Vedanthan , Stephanie H Cook , Rumi Chunara doi: https (...) ://doi.org/10.1101/2020.09.11.20192989 Yuan Zhao 1 New York University; Erica P Wood 1 New York University; Nicholas Mirin 1 New York University; Rajesh Vedanthan 2 New York University School of Medicine; Stephanie H Cook 3 New York University Rumi Chunara 1 New York University; For correspondence: Abstract Background: Cardiovascular disease (CVD) is the number one cause of death worldwide, and CVD burden is increasing in low-resource settings and for lower socioeconomic groups worldwide. Machine

2020 Cold Spring Harbor Laboratory

25. Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. (Abstract)

Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. This is the second update of the review first published in 2017. Hypertension is a prominent preventable cause of premature morbidity and mortality. People with hypertension and established cardiovascular disease are at particularly high risk, so reducing blood pressure to below standard targets may be beneficial. This strategy could reduce cardiovascular mortality and morbidity but could also (...) increase adverse events. The optimal blood pressure target in people with hypertension and established cardiovascular disease remains unknown.To determine if lower blood pressure targets (135/85 mmHg or less) are associated with reduction in mortality and morbidity as compared with standard blood pressure targets (140 to 160/90 to 100 mmHg or less) in the treatment of people with hypertension and a history of cardiovascular disease (myocardial infarction, angina, stroke, peripheral vascular occlusive

2020 Cochrane

26. Cardiovascular and Renal Outcomes with SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis Full Text available with Trip Pro

Cardiovascular and Renal Outcomes with SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis Cardiovascular and Renal Outcomes with SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis | Research Square Browse Tools & Services Your Cart See the published version (...) the effect of SGLT-2 inhibitors with that of GLP-1 RAs in type 2 DM patients with chronic kidney disease (CKD). We herein investigated the benefits of SGLT-2 inhibitors and GLP-1 RAs in CKD patients. Methods We performed a systematic literature search through July 2020. We selected randomized control trials that compared the risk of major adverse cardiovascular events (MACE) and a composite of renal outcomes. We performed a network meta-analysis to compare SGLT-2 inhibitors with GLP-1 RA indirectly. Risk

2020 Research Square

27. 2020 ESC Guidelines on Sports Cardiology and Exercise in Patients with Cardiovascular Disease Full Text available with Trip Pro

testing, field testing and/or after muscular strength testing 13 Figure 3a and 3b SCORE charts for European populations of countries at HIGH and LOW cardiovascular disease risk 15 Figure 4 Proposed algorithm for cardiovascular assessment in asymptomatic individuals with risk factors for and possible subclinical chronic coronary syndrome before engaging in sports for individuals aged >35 years 18 Figure 5 Clinical evaluation and recommendations for sports participation in individuals with established (...) Bicuspid aortic valve BMI Body mass index BP Blood pressure BrS Brugada syndrome CAC Coronary artery calcium CAD Coronary artery disease CCS Chronic coronary syndrome CCTA Coronary computed tomography angiography CHD Congenital heart disease CKD Chronic kidney disease CMD Coronary microvascular dysfunction CMR Cardiac magnetic resonance CPET Cardiopulmonary exercise test CPR Cardiopulmonary resuscitation CT Computed tomography CV Cardiovascular CVA Cerebrovascular accident CVD Cardiovascular disease

2020 European Society of Cardiology

28. Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk

Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public health information from CDC: . Get the latest research from NIH (...) Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation J Am Coll Cardiol Actions . 2020 Aug 18;76(7):781-793. doi: 10.1016/j.jacc.2020.06.040. Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk , , , , , , , , , Affiliations Expand Affiliations 1 Emory

2020 EvidenceUpdates

29. Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial Full Text available with Trip Pro

in both groups across all categories of eGFR. Conclusions: In patients with recent ACS, alirocumab was associated with fewer cardiovascular events and deaths across the range of renal function studied, with larger relative risk reductions in those with eGFR > 60 mL/min/1.73 m2. Keywords: Acute coronary syndrome; Chronic kidney disease; Glomerular filtration rate; Low-density lipoprotein cholesterol; Major adverse cardiovascular events; PCSK9 inhibition. © The Author(s) 2020. Published by Oxford (...) Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial - PubMed This site needs JavaScript to work properly. Please enable

2020 EvidenceUpdates

30. Systematic review of frameworks used to conceptualise health pathways of individuals diagnosed with cardiovascular diseases Full Text available with Trip Pro

(termed cognitive representations) motivates the degree to which they take action to improve their health status. The original framework viewed individual perceptions of illness as resulting from five factors: illness identity (label or disease name and perceptions of associated symptoms), their causes (factors and/or behaviours predisposing an individual to the condition), consequences (personal impact of the condition, including experienced and anticipated physical, cognitive and social disruption (...) ), control (behaviours to regulate the condition) and timeline of the illness (individual perceptions about the duration of illness; chronological aspects of the disease course and management). More recent iterations of the framework separated the control factor into treatment control and personal control. Proponents of the common-sense self-regulation model argue that the framework offers insights into individual differences in how illnesses are perceived, and how this influences behaviour regarding

2020 BMJ global health

31. Ethnic Disparities in Atherosclerotic Cardiovascular Disease Incidence and Prevalence Among Rheumatoid Arthritis Patients in the United States: a Systematic Review Full Text available with Trip Pro

Ethnic Disparities in Atherosclerotic Cardiovascular Disease Incidence and Prevalence Among Rheumatoid Arthritis Patients in the United States: a Systematic Review Ethnic Disparities in Atherosclerotic Cardiovascular Disease Incidence and Prevalence Among Rheumatoid Arthritis Patients in the United States: a Systematic Review - Daniel - 2020 - ACR Open Rheumatology - Wiley Online Library Working off-campus? Learn about our By continuing to browse this site, you agree to its use of cookies (...) as described in our . Search within Search term Search term Original Article Open Access Ethnic Disparities in Atherosclerotic Cardiovascular Disease Incidence and Prevalence Among Rheumatoid Arthritis Patients in the United States: a Systematic Review Corresponding Author University of Texas Southwestern Medical Center, Dallas, Texas Address correspondence to Christina M. Daniel, MD, University of Texas Southwestern Medical Center, Division of Rheumatology, 2001 Inwood Road, 8th floor, Dallas, TX 75390. E

2020 ACR open rheumatology

32. Reduction in saturated fat intake for cardiovascular disease. (Abstract)

to alter dietary fats and achieving a reduction in saturated fat; 3) compared with higher saturated fat intake or usual diet; 4) not multifactorial; 5) in adult humans with or without cardiovascular disease (but not acutely ill, pregnant or breastfeeding); 6) intervention duration at least 24 months; 7) mortality or cardiovascular morbidity data available.Two review authors independently assessed inclusion, extracted study data and assessed risk of bias. We performed random-effects meta-analyses, meta (...) Reduction in saturated fat intake for cardiovascular disease. Reducing saturated fat reduces serum cholesterol, but effects on other intermediate outcomes may be less clear. Additionally, it is unclear whether the energy from saturated fats eliminated from the diet are more helpfully replaced by polyunsaturated fats, monounsaturated fats, carbohydrate or protein.To assess the effect of reducing saturated fat intake and replacing it with carbohydrate (CHO), polyunsaturated (PUFA

2020 Cochrane

33. A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease Full Text available with Trip Pro

A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease | medRxiv Search for this keyword A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease Samarthkumar Thakkar , Shilpkumar Arora , Ashish Kumar , Rahul Jaswaney , Mohammed Faisaluddin , Mohammad Ammad Ud Din , Mariam (...) , Rochester, Minnesota, USA Abhishek Deshmukh 10 Department of Cardiovascular Medicine, Mayo Clinic , Rochester, Minnesota, USA For correspondence: ABSTRACT The impact of coronavirus disease, 2019 (COVID-19), has been profound. Though COVID-19 primarily affects the respiratory system, it has also been associated with a wide range of cardiovascular (CV) manifestations portending extremely poor prognosis. The principal hypothesis for CV involvement is through direct myocardial infection and systemic

2020 Cold Spring Harbor Laboratory

34. Diet and Cardiovascular Disease Risk Among Individuals with Familial Hypercholesterolemia: Systematic Review and Meta-Analysis Full Text available with Trip Pro

Diet and Cardiovascular Disease Risk Among Individuals with Familial Hypercholesterolemia: Systematic Review and Meta-Analysis Diet and Cardiovascular Disease Risk Among Individuals with Familial Hypercholesterolemia: Systematic Review and Meta-Analysis[v1] | Preprints Share this article with Create alert Email: Submit > > > doi: 10.20944/preprints202008.0174.v1 Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed Diet and Cardiovascular Disease Risk Among (...) Individuals with Familial Hypercholesterolemia: Systematic Review and Meta-Analysis , , , * Version 1 : Received: 5 August 2020 / Approved: 7 August 2020 / Online: 7 August 2020 (06:13:47 CEST) A of this Preprint also exists. Barkas, F.; Nomikos, T.; Liberopoulos, E.; Panagiotakos, D. Diet and Cardiovascular Disease Risk Among Individuals with Familial Hypercholesterolemia: Systematic Review and Meta-Analysis. Nutrients 2020 , 12 , 2436. Barkas, F.; Nomikos, T.; Liberopoulos, E.; Panagiotakos, D. Diet

2020 MDPI AG

35. Genetic Testing for Inherited Cardiovascular Diseases: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

published 23 Jul 2020 Circulation: Genomic and Precision Medicine. ;0 Abstract Advances in human genetics are improving the understanding of a variety of inherited cardiovascular diseases, including cardiomyopathies, arrhythmic disorders, vascular disorders, and lipid disorders such as familial hypercholesterolemia. However, not all cardiovascular practitioners are fully aware of the utility and potential pitfalls of incorporating genetic test results into the care of patients and their families (...) Genetic Testing for Inherited Cardiovascular Diseases: A Scientific Statement From the American Heart Association Genetic Testing for Inherited Cardiovascular Diseases: A Scientific Statement From the American Heart Association | Circulation: Genomic and Precision Medicine Search Search Hello Guest! Login to your account Email Password Keep me logged in Search Search 2020 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access Review Article

2020 American Heart Association

36. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. Full Text available with Trip Pro

Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. To evaluate the associations between prediabetes and the risk of all cause mortality and incident cardiovascular disease in the general population and in patients with a history of atherosclerotic cardiovascular disease.Updated meta-analysis.Electronic databases (PubMed, Embase, and Google Scholar) up to 25 April 2020.Prospective cohort studies or post hoc analysis of clinical (...) trials were included for analysis if they reported adjusted relative risks, odds ratios, or hazard ratios of all cause mortality or cardiovascular disease for prediabetes compared with normoglycaemia. Data were extracted independently by two investigators. Random effects models were used to calculate the relative risks and 95% confidence intervals. The primary outcomes were all cause mortality and composite cardiovascular disease. The secondary outcomes were the risk of coronary heart disease

2020 BMJ

37. Cardiovascular Implications of Coronavirus Disease 2019 (COVID-19): A Systematic Review Full Text available with Trip Pro

. Conclusion: Acute cardiac injury is common in patients with COVID-19. Aggressive supportive management based on prognostic indicators along with management of heart failure, arrhythmias, acute coronary syndrome and thrombosis can improve clinical outcomes in such patients. Keywords Coronavirus disease-2019, COVID-19, Cardiovascular implications, Acute cardiac injury, Death Figures Figure 1 Figure 2 Introduction Methods Results Discussion Conclusion Declarations References Tables Comments (0) 1 comment (...) Cardiovascular Implications of Coronavirus Disease 2019 (COVID-19): A Systematic Review Cardiovascular Implications of Coronavirus Disease 2019 (COVID-19): A Systematic Review | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its

2020 Research Square

38. Noncoding RNAs in Cardiovascular Disease: Current Knowledge, Tools and Technologies for Investigation, and Future Directions: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

Noncoding RNAs in Cardiovascular Disease: Current Knowledge, Tools and Technologies for Investigation, and Future Directions: A Scientific Statement From the American Heart Association Noncoding RNAs in Cardiovascular Disease: Current Knowledge, Tools and Technologies for Investigation, and Future Directions: A Scientific Statement From the American Heart Association | Circulation: Genomic and Precision Medicine Search Search Hello Guest! Login to your account Email Password Keep me logged (...) in Search Search 2020 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access Review Article Share on Jump to Free Access Review Article Noncoding RNAs in Cardiovascular Disease: Current Knowledge, Tools and Technologies for Investigation, and Future Directions: A Scientific Statement From the American Heart Association , MD, PhD, Chair , MD, FAHA, Co-chair , PhD, FAHA , MD, FAHA , MD, PhD , MD, PhD, FAHA , PhD, FAHA , MD, PhD, FAHA , PhD, FAHA , MD

2020 American Heart Association

39. Effect of a Comprehensive Cardiovascular Risk Reduction Intervention in Persons With Serious Mental Illness: A Randomized Clinical Trial Full Text available with Trip Pro

Abstract Importance: Persons with serious mental illness have a cardiovascular disease mortality rate more than twice that of the overall population. Meaningful cardiovascular risk reduction requires targeted efforts in this population, who often have psychiatric symptoms and cognitive impairment. Objective: To determine the effectiveness of an 18-month multifaceted intervention incorporating behavioral counseling, care coordination, and care management for overall cardiovascular risk reduction (...) in adults with serious mental illness. Design, setting, and participants: This randomized clinical trial was conducted from December 2013 to November 2018 at 4 community mental health outpatient programs in Maryland. The study recruited adults with at least 1 cardiovascular disease risk factor (hypertension, diabetes, dyslipidemia, current tobacco smoking, and/or overweight or obesity) attending the mental health programs. Of 398 participants screened, 269 were randomized to intervention (132

2020 EvidenceUpdates

40. Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial Full Text available with Trip Pro

Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable (...) Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Circulation Actions . 2020 Jun 9;141(23):1841-1854. doi: 10.1161/CIRCULATIONAHA.120.046448. Epub 2020 Mar 28. Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial , , , , , , , , , , , , , , , , , , , , Collaborators, Affiliations Expand Collaborators COMPASS Steering

2020 EvidenceUpdates